[The mode of action and clinical applications of phosphodiesterase inhibitors as anti-platelet drugs].
Murohara
Y
Y
Takatsu
Y
Y
Yui
Y
Y
Kawai
C
C
D015105:3',5'-Cyclic-AMP Phosphodiesterases / Q000037:antagonists & inhibitors / Q000627:therapeutic use; D000077407:Cilostazol; D003327:Coronary Disease / Q000188:drug therapy*; D003328:Coronary Thrombosis / Q000188:drug therapy*; D000242:Cyclic AMP / Q000097:blood / Q000502:physiology; D004176:Dipyridamole / Q000627:therapeutic use; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D006801:Humans; D010726:Phosphodiesterase Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D010974:Platelet Aggregation / Q000187:drug effects; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D011799:Quinazolines / Q000627:therapeutic use; D013777:Tetrazoles / Q000627:therapeutic use
D005343:Fibrinolytic Agents; D010726:Phosphodiesterase Inhibitors; D010975:Platelet Aggregation Inhibitors; D011799:Quinazolines; D013777:Tetrazoles; D004176:Dipyridamole; C049662:1,5-dihydro-7-(1-piperidinyl)-imidazo(2,1-b)quinazolin-2(3H)-one; D000242:Cyclic AMP; D015105:3',5'-Cyclic-AMP Phosphodiesterases; D000077407:Cilostazol